Downregulation of hTERT: An important As2O3 induced mechanism of apoptosis in myelodysplastic syndrome

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Xu, Weilai ^a   Wang, Yungui ^a   Tong, Hongyan ^a   Qian, Wenbin ^a   Jin, Jie ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; CASPASE 8; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; PYRROLIDINE DITHIOCARBAMATE; TELOMERASE REVERSE TRANSCRIPTASE; ORGANOARSENIC DERIVATIVE; OXIDE; PROTEIN BCL X; PROTEIN BINDING; TELOMERASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

AGED; APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRESCHOOL CHILD; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

AGED; APOPTOSIS; ARSENICALS; BCL-X PROTEIN; BLOTTING, WESTERN; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD, PRESCHOOL; DOWN-REGULATION; FEMALE; HUMANS; MYELODYSPLASTIC SYNDROMES; NF-KAPPA B; OXIDES; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SP1 TRANSCRIPTION FACTOR; TELOMERASE; TRANSCRIPTION FACTOR AP-1; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84913559589     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113199     Document Type: Article

References (32)

1. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, et al. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360.
2. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, et al. (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New Engl J Med 339: 1341-1348.
3. Niu C, Yan H, Yu T, Sun HP, Liu JX, et al. (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94: 3315-3332.
4. Rojewski MT, Baldus C, Knauf W, Thiel E, Schrezenmeier H (2002) Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia cell lines: induction of apoptosis and inhibition of proliferation. Br J Hematol 116: 555-563.
5. Kajiguchi T, Yamamoto K, Hossain K, Akhand AA, Nakashima I, et al. (2003) Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)- derived cell line, NKM-1. Leukemia 17: 2189-2195.
6. Rousselot P, Larghero J, Arnulf B, Poupon J, Royer B, et al. (2004) A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia 18(9): 1518-1521.
7. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI (2002) Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 8(2): 566-572.
8. Sekeres MA (2005) Arsenic trioxide as a treatment for myelodysplastic syndrome. Curr Hematol Rep 4(1): 59-63.
9. Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, et al. (2005) NF-{kappa}B and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDS). Blood 106(12): 3917-3925.
10. Raza A, Buonamici S, Lisak L, Tahir S, Li D, et al. (2004) Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 28: 791-803.
11. Qian W, Liu J, Jin J, Ni W, Xu W (2007) Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1.Leuk Res. Leuk Res 31(3): 329-339.
12. Hermine O, Dombret H, Poupon J, Arnulf B, Lefrere F, et al. (2004) Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 5(2): 130-134.
13. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, et al. (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARa/PML proteins. Blood 88: 1052-1061.
14. Zhou C, Boggess JF, Bae-Jump V, Gehrig PA (2007) Induction of apoptosis and inhibition of telomerase activity by arsenic trioxide (As2O3) in endometrial carcinoma cells. Gynecol Oncol 105(1): 218-222.
15. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, et al. (2003) Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 102(3): 1028-1034.
16. Jing YW, Yi J, Chen YY, Hu QS, Shi GY, et al. (2004) Dicoumarol alters cellular redox state and inhibits nuclear factor kappa B to enhance arsenic trioxide-induced apoptosis. Acta Biochim Biophys Sin (Shanghai) 36(3): 235-242.
17. Gorbunova V, Seluanov A (2003) Telomerase as a growth-promoting factor. Cell Cycle 2(6): 534-537.
18. Poole JG, Andrews LG, Tollefsbol TO (2001) Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 269(1-2): 1-12.
19. Sinha-Datta U, Horikawa I, Michishita E, Datta A, Sigler-Nicot JC, et al. (2004) Transcriptional activation of hTERT through the NF-kappaB pathway in HTLV-I-transformed cells. Blood 104(8): 2523-2531.
20. Steube KG, Gignac SM, Hu ZB, Teepe D, Harms D, et al. (1997) In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line MUTZ-1. Leuk Lymphoma 25(3-4): 345-363.
21. Nakagawa T, Matozaki S, Murayama T, Nishimura R, Tsutsumi M, et al. (1993) Establishment of a leukaemic cell line from a patient with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome. Br J Haematol. 85(3): 469-476.
22. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, et al. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89: 3345-3353.
23. Delhommeau F, Thierry A, Feneux D, Lauret E, Leclercq E, et al. (2002) Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant. Oncogene 21(54): 8262-8271.
24. Dubrana K, Perrod S, Gasser SM (2001) Turning telomeres off and on. Curr Opin Cell Biol 13(3): 281-289.
25. Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, et al. (2002) Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 99(20): 12606-12611.
26. Stewart SA (2005) Telomere maintenance and tumorigenesis: an ''ALT'' ernative road. Curr Mol Med 5(2): 253-257.
27. Chou WC, Chen HY, Yu SL, Cheng L, Yang PC, et al. (2005) Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood 106(1): 304-310.
28. Feinman R, Siegel DS, Berenson J (2004) Regulation of NF-kB in multiple myeloma: therapeutic implications. Clin Adv Hematol Oncol 2(3): 162-166.
29. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, et al. (2003) Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res 63(1): 18-21.
30. Qiao L, Yu J, Dent P, Farrell G (2005) NF-kappaB Protects Rat ARL-6 Hepatocellular Carcinoma Cells Against Hydrogen Peroxide-Induced Apoptosis. Cancer Biol Ther 4(11): 1195-1202.
31. Sanz C, Richard C, Prosper F, Fernandez-Luna JL (2002) Nuclear factor k B is activated in myelodysplastic bone marrow cells. Haematologica 87(9): 1005-1006.
32. Woo SH, Park IC, Park MJ, An S, Lee HC, et al. (2004) Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappaB activation. Int J Cancer 112(4): 596-606.